drugset / Trial / NCT02332954

Assessment in Work Productivity and the Relationship With Cognitive Symptoms in Patients With MDD Taking Vortioxetine

NCT02332954

Phase 4 Completed 226 enrolled Lundbeck Canada Inc.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to describe the association/correlation between change in patient-reported cognitive symptoms and work productivity in gainfully employed patients receiving vortioxetine for a Major Depressive Episode (MDE).

Timeline

Start
2015-02
Primary completion
2017-07-06
Completion
2017-07-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Vortioxetine Unknown 10 mg Oral
Subject Vortioxetine Unknown 20 mg Oral